Skip to main content
Erschienen in: Current Bladder Dysfunction Reports 2/2017

01.04.2017 | BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms

verfasst von: Grace E. Kohn, Taylor P. Kohn, Ranjith Ramasamy

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

While early studies suggested that testosterone replacement therapy would enlarge the prostate and worsen lower urinary tract symptoms, this review seeks to examine the combined evidence of observational studies, randomized control trials, and meta-analyses published on the topic to determine if testosterone replacement therapy worsens lower urinary tract symptoms in hypogonadal men.

Recent Findings

The combined evidence of 15 randomized control trials and 2 meta-analyses has demonstrated emphatically that testosterone replacement therapy has no effect on lower urinary tract symptoms in hypogonadal men with mild and moderate symptoms.

Summary

No randomized control trial has sufficiently examined the effect of testosterone replacement therapy in men with severe lower urinary tract symptoms. While a few observational studies have seen no effect when hypogonadal men with severe lower urinary tract symptoms are treated with testosterone replacement therapy, future randomized controlled trials specifically studying the effect of testosterone on men with severe lower urinary tract symptoms are warranted. In summary, clinicians should rest assured that testosterone does not worsen lower urinary tract symptoms in hypogonadal men with mild or moderate lower urinary tract symptoms.
Literatur
1.
Zurück zum Zitat Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. The aging male: the official journal of the International Society for the Study of the Aging Male. 2012;15(4):198–207. doi:10.3109/13685538.2012.699562.CrossRef Behre HM, Tammela TL, Arver S, Tolra JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. The aging male: the official journal of the International Society for the Study of the Aging Male. 2012;15(4):198–207. doi:10.​3109/​13685538.​2012.​699562.CrossRef
2.
Zurück zum Zitat Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98. doi:10.1210/jcem.87.2.8201.CrossRefPubMed Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98. doi:10.​1210/​jcem.​87.​2.​8201.CrossRefPubMed
3.
Zurück zum Zitat Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31. doi:10.1210/jcem.86.2.7219.CrossRefPubMed Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31. doi:10.​1210/​jcem.​86.​2.​7219.CrossRefPubMed
4.
Zurück zum Zitat Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78. doi:10.1210/jcem.84.10.6078.PubMed Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78. doi:10.​1210/​jcem.​84.​10.​6078.PubMed
6.
Zurück zum Zitat Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7. doi:10.1210/jcem.85.8.6731.PubMed Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2670–7. doi:10.​1210/​jcem.​85.​8.​6731.PubMed
7.
Zurück zum Zitat Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. The Journal of Clinical Endocrinology & Metabolism. 1996;81(10):3578–83. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. The Journal of Clinical Endocrinology & Metabolism. 1996;81(10):3578–83.
8.
Zurück zum Zitat Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men 1. The Journal of Clinical Endocrinology & Metabolism. 2000;85(8):2839–53. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men 1. The Journal of Clinical Endocrinology & Metabolism. 2000;85(8):2839–53.
10.
11.
Zurück zum Zitat Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 64PubMed Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 64PubMed
13.
Zurück zum Zitat •• Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22. doi:10.1016/j.eururo.2013.03.042. This meta-analysis demonstrates that prostate size does not change in hypogonadal men undergoing androgen replacement therapy. •• Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22. doi:10.​1016/​j.​eururo.​2013.​03.​042. This meta-analysis demonstrates that prostate size does not change in hypogonadal men undergoing androgen replacement therapy.
14.
Zurück zum Zitat Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The aging male : the official journal of the International Society for the Study of the Aging Male. 2011;14(1):53–8. doi:10.3109/13685538.2010.518178.CrossRef Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The aging male : the official journal of the International Society for the Study of the Aging Male. 2011;14(1):53–8. doi:10.​3109/​13685538.​2010.​518178.CrossRef
15.
Zurück zum Zitat • Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81. doi:10.1001/jama.2015.8881. In this recently published randomized control trial of 248 hypogondal men, the authors demonstrate no clinically or statistically significant increase in lower urinary tract symptoms after 3 years of testosterone replacement therapy. • Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81. doi:10.​1001/​jama.​2015.​8881. In this recently published randomized control trial of 248 hypogondal men, the authors demonstrate no clinically or statistically significant increase in lower urinary tract symptoms after 3 years of testosterone replacement therapy.
16.
Zurück zum Zitat Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007;19(4):411–7. doi:10.1038/sj.ijir.3901562.CrossRefPubMed Chiang HS, Hwang TI, Hsui YS, Lin YC, Chen HE, Chen GC, et al. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res. 2007;19(4):411–7. doi:10.​1038/​sj.​ijir.​3901562.CrossRefPubMed
17.
Zurück zum Zitat Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602–12. doi:10.1111/j.1365-2265.2010.03845.x.CrossRef Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602–12. doi:10.​1111/​j.​1365-2265.​2010.​03845.​x.CrossRef
18.
Zurück zum Zitat Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266–72.CrossRefPubMed Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266–72.CrossRefPubMed
19.
Zurück zum Zitat •• Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016; doi:10.1016/j.eururo.2016.01.043. This meta-analysis demonstrates that lower urinary tract symptoms are not worsened in hypogonadal men undergoing testosterone replacement therapy. •• Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016; doi:10.​1016/​j.​eururo.​2016.​01.​043. This meta-analysis demonstrates that lower urinary tract symptoms are not worsened in hypogonadal men undergoing testosterone replacement therapy.
20.
Zurück zum Zitat Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian journal of andrology. 2015; doi:10.4103/1008-682x.148720.PubMedCentral Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian journal of andrology. 2015; doi:10.​4103/​1008-682x.​148720.PubMedCentral
21.
Zurück zum Zitat Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61. doi:10.1001/jama.296.19.2351.CrossRefPubMed Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61. doi:10.​1001/​jama.​296.​19.​2351.CrossRefPubMed
22.
Zurück zum Zitat Meuleman EJ, Legros JJ, Bouloux PM, Johnson-Levonas AO, Kaspers MJ, Elbers JM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015;18(3):157–63. doi:10.3109/13685538.2015.1032925. Meuleman EJ, Legros JJ, Bouloux PM, Johnson-Levonas AO, Kaspers MJ, Elbers JM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015;18(3):157–63. doi:10.​3109/​13685538.​2015.​1032925.
23.
Zurück zum Zitat Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100(8):2956–62. doi:10.1210/jc.2014-4434. Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100(8):2956–62. doi:10.​1210/​jc.​2014-4434.
24.
Zurück zum Zitat Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50. doi:10.1210/jc.2009-1251.CrossRefPubMed Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50. doi:10.​1210/​jc.​2009-1251.CrossRefPubMed
25.
Zurück zum Zitat Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111(7):1130–40. doi:10.1111/bju.12037.CrossRefPubMed Tan WS, Low WY, Ng CJ, Tan WK, Tong SF, Ho C, et al. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study. BJU Int. 2013;111(7):1130–40. doi:10.​1111/​bju.​12037.CrossRefPubMed
26.
Zurück zum Zitat Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging. 1997;10(5):349–66.CrossRefPubMed Tammela T. Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging. 1997;10(5):349–66.CrossRefPubMed
27.
28.
Zurück zum Zitat Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354.CrossRefPubMed Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.​1210/​jc.​2009-2354.CrossRefPubMed
29.
Zurück zum Zitat Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106. doi:10.1002/pros.2990230203.CrossRefPubMed Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106. doi:10.​1002/​pros.​2990230203.CrossRefPubMed
30.
Zurück zum Zitat Brock G, Heiselman D, Maggi M, Kim SW, Rodriguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705. doi:10.1016/j.juro.2015.10.083.CrossRefPubMed Brock G, Heiselman D, Maggi M, Kim SW, Rodriguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195(3):699–705. doi:10.​1016/​j.​juro.​2015.​10.​083.CrossRefPubMed
31.
Zurück zum Zitat Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama. 2008;299:39. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Jama. 2008;299:39.
Metadaten
Titel
Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms
verfasst von
Grace E. Kohn
Taylor P. Kohn
Ranjith Ramasamy
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 2/2017
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-017-0419-2

Weitere Artikel der Ausgabe 2/2017

Current Bladder Dysfunction Reports 2/2017 Zur Ausgabe

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Meditate Temporary Implantable Nitinol Device

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Urinary Biomarkers for Bladder Outlet Obstruction

Cancer-Associated Voiding Dysfunction (A Peterson, Section Editor)

The Male Transobturator Sling for Stress Incontinence After the Treatment of Prostate Cancer

BPH-Related Voiding Dysfunction (R Lee, Section Editor)

Accurate Estimation of Prostate Size in the Evaluation of Nocturia

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.